Segmentation, Major Trends, and Competitive Overview of the Pleural Diseases Market

The pleural diseases market is on track for significant expansion in the coming years, driven by advances in diagnostics and treatment options. With growing focus on early detection and personalized care, this sector is set to witness notable developments by 2030. Let's explore the market's projected size, major players, emerging trends, and detailed segment breakdowns.

Projected Market Size and Growth Outlook for Pleural Diseases
The global pleural diseases market is forecasted to reach a value of $7.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1%. This robust growth is fueled by increasing investments in early cancer detection technologies, rising demand for minimally invasive diagnostic procedures, and the broader adoption of precision medicine approaches. Additionally, a heightened emphasis on outpatient respiratory care and continuous advancements in therapeutics for pleural diseases contribute to this positive trajectory. Key trends shaping the market include the widespread use of advanced imaging diagnostics, greater incorporation of molecular diagnostic methods, a surge in minimally invasive pleural interventions, expansion of early disease screening programs, and a stronger focus on customized treatment options.

Download a free report of the pleural diseases market report:
https://www.thebusinessresearchcompany.com/report/pleural-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving Innovation in the Pleural Diseases Market
Several prominent organizations play a pivotal role in the pleural diseases industry. Some of the key players include Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton dic*kinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, and Rocket Medical.

Noteworthy Acquisition Enhances Pleural Disease Pipeline
In October 2023, Aileron Therapeutics Inc., a US-based biopharmaceutical firm, completed the acquisition of Lung Therapeutics Inc. for an undisclosed amount. This strategic move strengthens Aileron's pipeline by adding Lung Therapeutics' candidates LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusions (LPEs). Lung Therapeutics specializes in developing innovative peptide drugs targeting fibrosis and rare pulmonary disorders, reinforcing the focus on orphan pulmonary and fibrosis diseases within the market.

View the full pleural diseases market report:
https://www.thebusinessresearchcompany.com/report/pleural-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Current Trends Driving the Pleural Diseases Market Forward
Industry leaders are increasingly concentrating on innovative treatment formats to improve patient convenience and safety. One notable trend is the development of ready-to-use injectable therapies, which eliminate the need for preparation or dilution, thereby reducing errors and saving time in clinical settings. These pre-formulated medications provide more accurate dosing and streamline administration processes.

An example of this innovation is Amneal Pharmaceuticals' recent launch in April 2024 of PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This advancement offers patients with pleural conditions, including malignant pleural mesothelioma, a more accessible and hassle-free treatment option that enhances therapeutic delivery by minimizing preparation steps and risks associated with dosing errors.

Detailed Segmentation of the Pleural Diseases Market
The pleural diseases market is categorized into several critical segments for a comprehensive understanding:

1) Disease Type:
- Pleurisy
- Pleural Effusion
- Pneumothelioma
- Mesothelioma
- Other Disease Types

2) Treatment Modalities:
- Medications
- Thoracentesis and Pleurodesis
- Minimally Invasive Interventions
- Surgical Interventions

3) Diagnostic Tools:
- Imaging Techniques
- Molecular Diagnostics
- Thoracoscopy
- Pleuroscopy

4) End Users:
- Hospitals and Clinics
- Diagnostic Centers
- Research and Academic Institutions

Subcategories further break down disease types to provide greater detail:

- Pleurisy includes acute, chronic, infectious, and non-infectious forms.
- Pleural Effusion covers transudative, exudative, malignant, parapneumonic, hemothorax, and chylothorax variants.
- Pneumothelioma is divided into primary, secondary (metastatic), localized, and diffuse types.
- Mesothelioma encompasses pleural mesothelioma, benign pleural tumors, pleural thickening disorders, and pleural plaques.
- Other diseases listed are empyema, fibrothorax, pneumothorax, lung cancer, tuberculosis-related pleural disease, and sarcoidosis.

This structured segmentation helps stakeholders and medical professionals better understand the scope of pleural diseases and tailor diagnostic and therapeutic approaches accordingly.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.